SUMMARY In a single-blind, randomised, crossover study in 10 asthmatic patients, the effects of approximately equipotent oral doses of 3 cardioselective beta-blockers-atenolol (100 mg), metoprolol (100 mg), and acebutolol (300 mg)-and 4 non-cardioselective beta-blockers-propranolol (100 mg), oxprenolol (100 mg), pindolol (5 mg), and timolol (10 mg) upon FEV1 were compared.
Hypertension, ischaemic heart disease, cardiac arrhythmias, and asthma are common conditions often occurring, in various combinations, in the same patient. Beta-adrenoreceptor antagonists (betablockers) are frequently administered for the first three ailments but are known to be potentially harmful to the asthmatic. Since the demise of practolol in 1975, there has been a need for a betablocker which might be given with relative safety to the asthmatic patient.
The present study was designed to assess the effect of 7 established beta-blockers upon the airways resistance of a group of patients with reversible airways obstruction. The 7 agents were: 2 noncardioselective beta-blockers with no intrinsic sympathomimetic activity-propranolol (Inderal), and timolol (Blocadren); 2 non-cardioselective betablockers with intrinsic sympathomimetic activitypindolol (Visken) and oxprenolol (Trasicor); 2 cardioselective beta-blockers with no intrinsic sympathomimetic activity-metoprolol (Lopressor or Betaloc) and atenolol (Tenormin); and 1 cardioselective agent with intrinsic sympathomimetic activity-acebutolol (Sectral). ' Present address: ICI Limited, Pharmaceuticals Division, Macclesfield, Cheshire.
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Methods
Ten asthmatic patients were included in the study, all with reversible airways obstruction. Clinical features are listed in Table 1 .
Five of the patients were seen at Wythenshawe Hospital, Manchester, and had previously been exposed (single-blind randomised, crossover) to single oral doses of propranolol (100 mg), metoprolol (100 mg), atenolol (100 mg), and placebo. All 5 patients had had a fall in FEV1 of at least 20 per cent to one or more of those beta-blockers. The study was extended so that 4 of the 5 patients received single oral doses (single-blind, randomised, crossover) of timolol (10 mg) and oxprenolol (100 mg).
The other 5 patients were seen at the Cardiothoracic Centre, Southampton, and had been previously exposed (under identical conditions to the Manchester study) to propranolol (100 mg), pindolol (5 mg), acebutolol (300 mg), atenolol (100 mg), and placebo. As before, all 5 patients had had a fall in FEV1 of at least 20 per cent to one or more of those beta-blockers. The study was extended so that 4 of the 5 patients received single oral doses (single-blind, randomised, crossover) of metoprolol (100 mg) and oxprenolol (100 mg). Drug dosage was chosen according to accepted beta blocking potency ratios in man (Thadani et al., To analyse the combined data set, an analysis of covariance was performed using the baseline for each treatment as the covariate. This was done twice, once with the group x drug interaction included, and once, after we had found nonsignificance, without.)
To check that the additional drugs (in the 2 extended studies) produced no sequential effect when added to the drugs in the 2 main studies, the metoprolol/placebo comparison (one in a main, and (n 10) (n 10) (n = 9) (n = 5) the other in an extended study) was examined. No significant difference was found.
Results
All drugs, with the exception of pindolol, were associated with an almost identical percentage decrease in standing heart rate ( Fig.) , thus confirming equipotency of beta-blockade. These results, again with the exception of pindolol, were statistically significantly (P < 0 05) slower than that associated with placebo. Isoprenaline caused a speeding of the pulse rate while patients were taking placebo, though this did not achieve statistical significance. The effects of drugs upon FVC, PEFR, and FEV1 were almost identical. For simplicity, results referring only to FEV1 will be presented. Table 2 shows the effect of the drugs and isoprenaline upon the FEV1 of the 10 patients. At some time during the study, 6 of the 10 patients complained of wheezing induced by one or more of the drugs. This was so for all 4 patients who received timolol; 6 of the 8 patients who received oxprenolol; 5 of the 10 patients who received propranolol; 4 of the 9 patients who received metoprolol; and 1 of the 5 patients who received both pindolol and acebutolol.
No wheezing was associated with either placebo or atenolol.
All drugs caused a fall in the mean FEV1 at 2 hours (Table 3 , Fig.) . The fall in FEV1 associated with atenolol, in contrast to all the other drugs, did not differ statistically significantly from placebo (Table 4 ). The falls in FEV1 associated with oxprenolol, pindolol, propranolol, and timolol were all statistically significantly greater than that seen with atenolol (Table 4 ).
The effects of isoprenaline (given 21 hours after drug administration) upon FEV1 are shown in Table 3 and the Fig. Only in the case of placebo and the 3 cardioselective drugs, atenolol, metoprolol, and acebutolol, was a bronchodilator action observed, achieving statistical significance in the case of placebo (P < 0X001), atenolol (P < 0-01), and metoprolol (P < 0 05).
The FEV1 achieved after isoprenaline exceeded baseline values only in the cases of placebo and atenolol (Table 3 , Fig.) . In a 'between-drug' comparison of the difference between initial and postisoprenaline FEV1 values ( iseline; 2 = 2 hours after treatment; Iso = Isoprenaline given 2i hours after treatment; n = number of patients.
given in italics indicate that the patient complained of wheeziness. 1-68; acebutolol, 1-67; pindolol, 0-56; and propranolol, 0-41. These laboratory data appear to be good predictors of how the various beta-blockers will behave when given to the asthmatic patient; particularly in relation to their modifying effect upon the bronchodilator action of isoprenaline, i.e. cardioselective, in contrast to non-cardioselective, agents permit a significant bronchodilatation. The study by Vilsvik and Schaanning (1976) , comparing Henningsen (1977) reported that of 17 hypertensive asthmatic patients taking atenolol, 16 were well on the drug after 3 years. Secondly, cardioselectivity is a dose-related quality (Lertora et al., 1975; Singh et al., 1975) . This point has been well shown in man (Formgren, 1976) where bronchospasm was induced by metoprolol at doses above 100 mg/day.
It was noteworthy that all the drugs blocked the beta-I effect of isoprenaline upon the pulse rate. The non-cardioselective drugs also blocked the beta-2 effect of isoprenaline upon the bronchi, in contrast to the drugs claiming cardioselectivity which permitted some bronchodilator activity. Again, this point was emphasised by Vilsvik in his atenolol/ practolol comparison.
In conclusion, no beta-blocker, even if claiming to be cardioselective, is absolutely safe for the asthmatic patient. Neither does the possession of intrinsic sympathomimetic activity appear to have a beneficial effect, as claimed by some investigators (Macdonald and McNeill, 1968; Paterson, 1971; Imhof, 1974) . However, the bronchodilator action of a beta-2 stimulant such as isoprenaline is best preserved by giving a cardioselective, rather than non-cardioselective, beta-blocker.
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